Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,318 papers from all fields of science
Search
Sign In
Create Free Account
Type 1 Papillary Renal Cell Carcinoma
Known as:
Papillary renal cell carcinoma type 1
, RCCP1
, RENAL CELL CARCINOMA, PAPILLARY, 1
A papillary renal cell carcinoma characterized by the presence of papillae covered by small cells with scant amount of cytoplasm. The cells are…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
19 relations
Bile Ducts, Extrahepatic
Cystic Change
Epithelial Cells
Epithelium
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
[Successful Treatment of Peritoneal Dissemination Recurrence with Axitinib in Papillary Renal Cell Carcinoma : A Case Report].
Jun-Ich Mori
,
Y. Nakayama
,
Tsuyoshi Hiragino
,
H. Matsuyama
Hinyokika kiyo. Acta urologica Japonica
2018
Corpus ID: 13865962
We report a case of successful treatment of recurrence of peritoneal dissemination with axitinib. A 55-year-old man presented at…
Expand
2018
2018
Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification: Final results of EORTC 90101 CREATE.
P. Schöffski
,
A. Wozniak
,
+15 authors
L. Albiges
2018
Corpus ID: 80219122
580Background: Papillary renal cell carcinoma type 1(PRCC1) is associated with MET alterations. Our phase II trial assessed the…
Expand
2018
2018
Abstract 3842: Potent antitumor activity of the HSP90 inhibitor SNX-2112 in type 1 papillary renal cell carcinoma
R. Pahwa
,
Abhigya Giri
,
+4 authors
R. Srinivasan
Experimental and Molecular Therapeutics
2018
Corpus ID: 81719323
Papillary renal-cell carcinoma (pRCC) is the second most common form of kidney cancer, accounting for 15 to 20% of all cases…
Expand
2018
2018
MP28-17 NON-TYPE 1 PAPILLARY RENAL CELL CARCINOMA IS ASSOCIATED WITH A WORST ONCOLOGICAL OUTCOME IN PATIENTS TREATED SURGICALLY
H. Slaoui
,
V. Verkarre
,
+12 authors
M. Timsit
2018
Corpus ID: 57931039
2017
2017
Type 1 papillary renal cell carcinoma: differentiation from Type 2 papillary RCC on multiphasic MDCT
J. Young
,
H. Coy
,
+4 authors
S. Raman
Abdominal Radiology
2017
Corpus ID: 9132010
PurposeTo investigate whether multiphasic MDCT enhancement can help differentiate type 1 papillary renal cell carcinoma (RCC…
Expand
2016
2016
Abstract CT006: Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somaticMETmutations…
P. Schöffski
,
A. Wozniak
,
+14 authors
L. Albiges
2016
Corpus ID: 78764077
Background: EORTC 90101 prospectively assesses the activity and safety of the ALK/ROS/MET inhibitor Crizotinib in 6 independent…
Expand
Review
2013
Review
2013
Transition of organizational category on renal cancer.
Y. Nagashima
,
N. Kuroda
,
M. Yao
Japanese Journal of Clinical Oncology
2013
Corpus ID: 13428746
The incidence of kidney cancer is gradually increasing, with a rate of 2-3% per decade. The kidney develops various kinds of…
Expand
2013
2013
Gastrointestinal stromal tumor associated with a different malignant neoplasia.
Ana I Sánchez-Garrido
,
M. Martín-Arribas
,
Ana-Beatriz Prieto-Bermejo
,
Concepción Piñero-Pérez
,
A. Rodríguez-Pérez
Revista Espanola de Enfermedades Digestivas
2013
Corpus ID: 22377064
The gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in the digestive tract (1). It is accompanied by…
Expand
2012
2012
Synchronous ipsilateral conventional and papillary renal cell carcinoma
A. Andreou
2012
Corpus ID: 75217287
2000
2000
Thomsen-Friedenreich glycotope is expressed in developing and normal kidney but not in renal neoplasms.
Valeriu Toma
,
C. Zuber
,
+5 authors
J. Roth
Human Pathology
2000
Corpus ID: 23648640
The Thomsen-Friedenreich glycotope (TF) is considered a general carcinoma autoantigen and is therefore of importance in cancer…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE